secretoglobin family 2B member 2Genealiases: SCGB4A2 · SCGBL
Q-omics provides the consensus-scored SCGB2B2 profile across patient tissues and cancer cell-line models. SCGB2B2 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, SCGB2B2 is differentially expressed in 7, with the highest sampling consensus in THCA. Additionally, SCGB2B2 RNA expression shows 18,828 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight UVM, THCA, and THYM as cancer lineages where SCGB2B2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SCGB2B2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SCGB2B2 survival associations across molecular data types. SCGB2B2 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SCGB2B2 RNA expression–survival associations across cancer types. High SCGB2B2 expression shows unfavorable associations in UCEC, but favorable associations in UVM, KIRP, HNSC, UCS and PAAD. The UVM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .004). Together, the overview and detailed table identify UVM as the clearest survival context for SCGB2B2 RNA expression.
This table summarizes SCGB2B2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for SCGB2B2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SCGB2B2 shows lower tumor expression in THCA, KICH and LUSC and higher tumor expression in STAD, PRAD and CHOL. The THCA box plot shows higher SCGB2B2 RNA expression in normal versus tumor tissue (log2 FC = −0.543, t-test p < 0.001).
This table shows molecular features associated with SCGB2B2 in patient tissues and cancer cell lines. In patient samples, SCGB2B2 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, SCGB2B2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in KIDNEY and BLOOD_Leukemia.
